Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Cash and Equivalents of $16.37 million for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $16.37M | -6.8% |
| 2024 | $17.57M | -21.6% |
| 2023 | $22.41M | -54.1% |
| 2022 | $48.82M | -86.6% |
| 2021 | $363.67M | -16.2% |
| 2020 | $434.22M | +4715.6% |
| 2019 | $9.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.44M | +45.6% | +21.4% |
| June 30, 2025 | $19.30M | +24.3% | -6.4% |
| March 31, 2025 | $20.61M | +46.8% | +17.3% |
| December 31, 2024 | $17.57M | -21.6% | +9.1% |
| September 30, 2024 | $16.10M | -17.8% | +3.7% |
| June 30, 2024 | $15.53M | -59.2% | +10.6% |
| March 31, 2024 | $14.04M | -77.8% | -37.3% |
| December 31, 2023 | $22.41M | -54.1% | +14.4% |
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -6.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, ALX ONCOLOGY HOLDINGS INC’s cash and equivalents has grown by 81.6% (from $9.02 million to $16.37 million).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: